Expertise in
23
conditions

Dr. Howard Colman

Neurology
1950 Circle Of Hope Dr, 
Salt Lake City, UT 
On Staff At
Accepting New Patients
Offers Telehealth
Referral may be required
Expertise in
23
conditions
1950 Circle Of Hope Dr, 
Salt Lake City, UT 

Overview

Howard Colman is a Neurologist practicing medicine in Salt Lake City, Utah.

Dr. Colman is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Astrocytoma, Glioblastoma, Glioma, and Brain Tumor.

Dr. Colman is board certified in American Board Of Surgery. He is actively involved in clinical research, co-authoring 119 peer reviewed articles and participating in 11 clinical trials. Dr. Colman is currently accepting new patients.

Graduate Institution

George Washington University School Of Medicine

Specialties

Neurology

Licenses

Psychiatry & Neurology in UT

Board Certifications

American Board Of Surgery

Hospital Affiliations

University Of Utah Hospital And Clinics

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BridgeSpan
  • EPO
  • HMO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Deseret Mutual Benefit Administrators
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Mountain Health
  • OTHER COMMERCIAL
  • POS
  • PPO
Regence
  • EPO
  • PPO
SelectHealth
  • HMO
  • POS
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
Steward Health Care
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
University of Utah Health
  • EPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Neuro Critical Care - Hci
1950 Circle Of Hope Dr, Salt Lake City, UT 84112
Other Locations
U Of U Neuro Critical Care
175 N Medical Dr, Salt Lake City, UT 84112
University Of Utah Department Of Neurosurgery-clinical Neuro
175 N Medical Dr, Salt Lake City, UT 84112
Neurosurgery - Som
50 N Medical Dr, Salt Lake City, UT 84132

Additional Areas of Focus

Dr. Colman has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Multicenter, Open-Label Study With a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy
A Multicenter, Open-Label Study With a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy
Enrollment Status: Active_not_recruiting
Publish Date: April 15, 2026
Intervention Type: Drug
Study Drugs: Berubicin, Lomustine
Study Phase: Phase 2
A Phase 1b Trial of Telaglenastat (CB-839) HCI in Combination With Radiation Therapy and Temozolomide in Patients With IDH-Mutated Diffuse Astrocytoma and Anaplastic Astrocytoma
A Phase 1b Trial of Telaglenastat (CB-839) HCI in Combination With Radiation Therapy and Temozolomide in Patients With IDH-Mutated Diffuse Astrocytoma and Anaplastic Astrocytoma
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Radiation, Drug, Other
Study Drugs: Telaglenastat Hydrochloride, Temozolomide
Study Phase: Phase 1
Genomically-Guided Treatment Trial in Brain Metastases
Genomically-Guided Treatment Trial in Brain Metastases
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Paxalisib, Entrectinib
Study Phase: Phase 2
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Drug
Study Drugs: Temozolomide, Veliparib
Study Phase: Phase 2/Phase 3
An Open-Label, Multi-Center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With REGN2810 in Subjects With Newly-Diagnosed Glioblastoma (GBM)
An Open-Label, Multi-Center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With REGN2810 in Subjects With Newly-Diagnosed Glioblastoma (GBM)
Enrollment Status: Active_not_recruiting
Publish Date: March 19, 2026
Intervention Type: Biological, Drug, Radiation
Study Drugs: INO-5401, INO-9012, Cemiplimab, Temozolomide
Study Phase: Phase 1/Phase 2
Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas
Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas
Enrollment Status: Active_not_recruiting
Publish Date: February 18, 2025
Intervention Type: Other, Drug
Study Drugs: Vemurafenib, Cobimetinib
Study Phase: Phase 2
A Phase 1b/2 Study to Assess the Safety, Tolerability and Efficacy of BGB-290 in Combination With Radiation Therapy (RT) and/or Temozolomide (TMZ) in Subjects With First-line or Recurrent/Refractory Glioblastoma
A Phase 1b/2 Study to Assess the Safety, Tolerability and Efficacy of BGB-290 in Combination With Radiation Therapy (RT) and/or Temozolomide (TMZ) in Subjects With First-line or Recurrent/Refractory Glioblastoma
Enrollment Status: Completed
Publish Date: February 04, 2025
Intervention Type: Drug, Radiation
Study Phase: Phase 1/Phase 2
A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, ALLIANCE IND # 15380) Vaccine Given With Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, ALLIANCE IND # 15380) Vaccine Given With Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
Enrollment Status: Terminated
Publish Date: January 24, 2025
Intervention Type: Biological, Drug
Study Drugs: HSPPC-96, Bevacizumab
Study Phase: Phase 2
A Phase 1/2 Study of Selinexor in Combination With Standard of Care (SoC) Therapy for Newly Diagnosed or Recurrent Glioblastoma
A Phase 1/2 Study of Selinexor in Combination With Standard of Care (SoC) Therapy for Newly Diagnosed or Recurrent Glioblastoma
Enrollment Status: Terminated
Publish Date: December 16, 2024
Intervention Type: Drug, Device, Radiation
Study Drugs: Selinexor, Temozolomide (TMZ), Lomustine (CCNU), Bevacizumab, Carmustine
Study Phase: Phase 1/Phase 2
A Phase I/II Study of the Combination of Indoximod and Temozolomide for Adult Patients With Temozolomide-Refractory Primary Malignant Brain Tumors
A Phase I/II Study of the Combination of Indoximod and Temozolomide for Adult Patients With Temozolomide-Refractory Primary Malignant Brain Tumors
Enrollment Status: Completed
Publish Date: March 27, 2024
Intervention Type: Drug, Radiation
Study Phase: Phase 1/Phase 2
View 9 Less Clinical Trials

118 Total Publications

Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.
Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 14, 2026
Similar Doctors
Expertise in
27
conditions
Dr. Stefan Pulst
Neurology
Expertise in
27
conditions
Dr. Stefan Pulst
Neurology

University Of Utah Hospital Neurology Department

50 N Medical Dr, 
Salt Lake City, UT 
 (0.1 miles away)
801-585-6387
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Stefan Pulst is a Neurologist practicing medicine in Salt Lake City, Utah. Dr. Pulst is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Olivopontocerebellar Atrophy, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia, Drug Induced Dyskinesia, and Deep Brain Stimulation. Dr. Pulst is board certified in American Board Of Psychiatry And Neurology. Dr. Pulst is currently accepting new patients.

Expertise in
37
conditions
Dr. William Couldwell
Neurology
Expertise in
37
conditions
Dr. William Couldwell
Neurology

University Of Utah Department Of Neurosurgery-Clinical Neuro

175 N Medical Dr, 
Salt Lake City, UT 
 (0.6 miles away)
801-585-7575
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

William Couldwell is a Neurologist practicing medicine in Salt Lake City, Utah. Dr. Couldwell is highly rated in 37 conditions, according to our data. His clinical expertise encompasses Meningioma, Pituitary Tumor, Pituitary Apoplexy, Nerve Decompression, and Cerebral Artery Bypass Surgery. Dr. Couldwell is board certified in American Board Of Neurological Surgery. Dr. Couldwell is currently accepting new patients.

Expertise in
15
conditions
Dr. Stacey Clardy
Neurology
Expertise in
15
conditions
Dr. Stacey Clardy
Neurology

Neurology - Inc

729 S Arapeen Dr, 
Salt Lake City, UT 
 (1.4 miles away)
801-585-6387
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Stacey Clardy is a Neurologist practicing medicine in Salt Lake City, Utah. Dr. Clardy is highly rated in 15 conditions, according to our data. Her clinical expertise encompasses Encephalitis, Stiff Person Syndrome, Neurosarcoidosis, and Anti-NMDA Receptor Encephalitis. Dr. Clardy is board certified in American Board Of Psychiatry And Neurology. Dr. Clardy is currently accepting new patients.

Frequently Asked Questions about Dr. Howard Colman

How do I make an appointment with Dr. Howard Colman?

You can book an appointment with Dr. Howard Colman by calling their office at 801-585-7575. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Howard Colman a top-rated expert for Astrocytoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Howard Colman is classified as an Elite expert for Astrocytoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Howard Colman specialize in?

While Dr. Howard Colman is a Neurology, they have specific expertise in Astrocytoma, Glioblastoma, and Glioma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Neurology.

Does Dr. Howard Colman participate in research or clinical trials?

Yes. Dr. Howard Colman has published 118 articles and abstracts on conditions like Astrocytoma. You can view a list of Dr. Howard Colman's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Howard Colman accept my insurance?

Dr. Howard Colman accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 801-585-7575 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Colman's expertise for a condition
ConditionClose
View All 10 Distinguished Conditions
View All 7 Advanced Conditions
View All 10 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile